Therapeutic opportunities emerging from HK isoform biology include the development of uMtCK inhibitors to disrupt HK2/JNK-mediated metastatic programming, PDLIM1-targeted proteolysis-targeting chimeras (PROTACs) for simultaneous HK2 catalytic inhibition and Wnt pathway blockade, and HKDC1-specific locked nucleic acid (LNA) gapmers designed to reverse EMT in advanced GC. Here, HK2 is linked to gastric cancer.